Seegene Appoints Richard Krieger as CEO of US Subsidiary... Full-Scale Entry into the US Market

Richard Krieger Appointed New CEO of Seegene USA Corporation

[Asia Economy Reporter Chunhee Lee] Seegene is hastening its full-scale preparations to enter the U.S. market by recruiting a new head of its U.S. subsidiary.

Molecular diagnostics specialist Seegene announced on the 2nd that it had appointed Richard Krieger as the CEO of its U.S. subsidiary as of the 28th of last month.

The United States is the largest molecular diagnostics market in the world, estimated to account for about half of the entire global market. Having relatively struggled to properly expand its business in the U.S. market, Seegene plans to use the appointment of CEO Krieger as a turning point to fully activate its U.S. operations.

CEO Krieger earned a Ph.D. in Microbiology from the University of Pittsburgh School of Medicine and subsequently worked for over 20 years at global bio company Beckman Coulter, overseeing all aspects of the molecular diagnostics business including research and development (R&D), clinical, manufacturing, and marketing as a division head. Recently, he founded the molecular diagnostics consulting firm 'NaviDx' and provided consulting services to bio companies. A Seegene official explained, "We decided to recruit the new CEO Krieger, who has diverse experience related to the molecular diagnostics business, as the optimal talent to spearhead the full-scale launch of our U.S. operations."

Through its U.S. subsidiary, Seegene plans to develop its own products and establish clinical and production capabilities in the mid to long term to target the North American market. CEO Krieger will oversee all aspects of Seegene’s U.S. business, including strengthening internal capabilities such as U.S. Food and Drug Administration (FDA) approvals, establishing local R&D and production facilities, as well as seeking growth opportunities through mergers and acquisitions (M&A).

CEO Krieger said, “I have worked in the molecular diagnostics field for over 30 years as an executive and consultant. Based on Seegene’s technology and infrastructure, I will actively contribute to growing the U.S. business and helping Seegene become the top global company in the molecular diagnostics field.”

This content was produced with the assistance of AI translation services.